Source: http://www.lawofcompoundingmedications.com/2012/07/jeffrey-n-gibbs-statement-on-behalf-of.html
Timestamp: 2014-11-01 13:33:30
Document Index: 606889676

Matched Legal Cases: ['§ 13', '§ 45', '§ 13', '§ 13', '§ 13', '§ 13', '§ 355', '§ 353', '§ 503', '§ 503']

The Law of Compounding Medications And Drugs: Jeffrey N. Gibbs Statement on Behalf of Dr. Gooberman's before NJ Board of Pharmacy Regarding Compounding Naltrexone Pellets
Jeffrey N. Gibbs Statement on Behalf of Dr. Gooberman's before NJ Board of Pharmacy Regarding Compounding Naltrexone Pellets
Jeffrey N. Gibbs, Esq.Hyman, Phelps & McNamara, P.C.Washington, D.C.Regulatory Counsel to Lance Gooberman, M.D.
New Jersey State Board of Medical ExaminersSpecial Committee Investigatory Hearing
This statement is provided on behalf of Dr. Lance Gooberman, M.D. It describes the legal and regulatory status of the practice of pharmacy compounding. It is offered to demonstrate that the practice of pharmacy compounding is legal under both federal law and New Jersey state law, that the regulatory requirements for ensuring the safety and effectiveness of compounded drugs differ significantly from the requirements for manufactured drug products, and that Dr. Gooberman's practice of compounding naltrexone pellets for subcutaneous implantation in patients undergoing opiate detoxification is consistent with those requirements.
Compounding is an integral part of the practice of pharmacy. It is legal in all fifty states. Tens of thousands of compounded dosage forms are dispensed each day in the United States.1
In New Jersey, compounding is defined as "the act of preparing pharmaceutical components into medications, pursuant to an authorized prescriber's medication order, including, but not limited to prescription compounding, and intravenous admixture preparation."2 Like other states, New Jersey state law imposes specific requirements on the practice of compounding. For example, specific New Jersey Statutes require compounded prescriptions to be filled in the amount and with the drugs as prescribed by the practitioners.3 limit who may compound drugs and under what conditions,4 and establish training,5 documentation,6 and handling and delivery requirements for compounded prescriptions.7
However, nothing in New Jersey law says that a pharmacist must have a specified amount of data before compounding a drug, or that a physician must have a specified amount of data before prescribing a Compound drug. And, in fact, requiring a specified amount of data in advance is entirely incompatible with compounding. Physicians often prescribe a compounded drug to meet the unique needs of a single patient. Obviously, there can be no prior clinical experience in that situation.
The practice of pharmacy compounding is distinctly different from the process of drug manufacturing. The U.S. Pharmacopoeia (USP), an authoritative reference for establishing drug standards, describes the characteristics that differentiate compounding from manufacturing. They include: "the existence of specific practitioner-pharmacist-patient relationships; the quantity of medication prepared in anticipation of receiving a prescription or a prescription order; and the conditions of sale, which are limited to specific prescription orders."8
The USP has established a monograph that describes the standards for pharmacy compounding. USP took this action in express recognition of the importance of compounding. Significantly, although USP sets our detailed standards for compounding, it does not require that there be test done before a drug is compounded. Similarly; the National Association of Boards of Pharmacy (NABP), to which most state boards of pharmacies belong, has created detailed standards for drug compounding, NABP's standards have been widely adopted by the states. However, the NABP's standards do not require that a pharmacist or physician possess any clinical data before compounding.
Compounding is most frequently necessary when the patient requires a drug that is not available commercially. Because approval of a new drug application is a time consuming and expensive process, manufacturers generally only develop drugs in the strengths and dosage forms that are most likely to ensure a return on their investment. If a particular patient needs a drug in a different strength or dosage form, compounding is the means by which the physician can provide the drug to that patient. Compounding is also useful for medications that are not stable and which must be prepared in small quantities, or when the patient is allergic to something (e.g. a dye) in the commercially available form of the drug.
In 1938, Congress passed the first statute regulating the distribution of drugs. As subsequently amended, federal law requires that before the drug may be marketed, the drug company must demonstrate that he drug is safe and effective for its intended use. As a result, drug companies must undertake one or more clinical studies of sufficient size to demonstrate the safety and effectiveness of the product.9 By contrast, a compounded drug is not intended for general use. Thus, the regulatory scheme for ensuring the safety and effectiveness of compounded drugs is necessarily different than that for manufactured drug products.
In 1997, Congress established the regulatory scheme that now governs the practice of pharmacy compounding. The strategies selected by Congress to ensure the safety and effectiveness of compounded drugs clearly reflect the characteristic differences between compounded and manufactured drug products. The federal regulatory scheme focuses on controlling the process of compounding. It does not require a statistically significant assessment of the safety and effectiveness of the final drug product, as that assessment would be irrelevant to the needs of the patient for whom the compounded prescription was prescribed.
Pharmacy Compounding: The Federal Regulatory Requirements
Prior to 1997, the Food and Drug Administration (FDA) had taken the position that pharmacies that compounded were subject to the new drug approval (NDA) and good manufacturing practice (GMP) requirements of the Federal Food, Drug, and Cosmetic Act (FDC Act). According to the FDA, every time a pharmacy compounded a drug, it needed to comply with the GMP and NDA provisions of the FDC Act. While FDA said that in the exercise of its enforcement discretion, it would normally not require pharmacies to comply with the GMP and NDA requirements, the agency also said that it had the power to compel compliance. Under those standards, compounded drugs were - n theory - subject to the same standards for safety and efficacy as drugs manufactured for use in the general population. Congress disagreed with that approach.
In 1997, Congress amended the FDC Act by adding Section 503A which governs the practice of pharmacy compounding. Section 503A which governs the practice of pharmacy compounding. Section 503A exempts compounded drugs from the new drug approval and good manufacturing practice requirements of the FDC Act, provided that the drugs are compounded in accordance with specified criteria. These criteria include limiting compounding to licensed pharmacists and physicians, and restricting the type and quality of the materials that may be used. It is through adherence to these criteria that the safety and efficacy of compounded drug products is achieved. Therefore, a pharmacist who compounds a drug in accordance with these criteria is exempt from the NDA, GMP and labeling provisions that govern the development of drug products manufactured for use in a broader population of patients.10 Thus, there are no requirements for evaluating the safety or efficacy of the final compounded drug in animal or human trials. The statute does not require test data even if a compounded drug is widely prescribed and dispensed to thousands of patients.
In enacting the pharmacy legislation, Congress was well aware of the fact that new drugs generally require controlled clinical trials. Nevertheless, Congress exempted compounded drugs from the need to meet this standard. Congress recognized that compounding, by its very nature, should not have to meet the safety and efficacy standards that apply to manufactured drugs.
Compounding of Depo-Naltrexone Pellets
Dr. Gooberman's practice of compounding depo-naltrexone in pellet form for subcutaneous implantation in patients undergoing opiate detoxification is consistent with the criteria established by Congress for pharmacy compounding in Section 503A. Section 503A provides that compounding may only be performed by a licensed pharmacist or licensed physician subject to receipt of a valid prescription for an identified Patient. Dr. Gooberman complies with this requirement because he, as a licensed physician, prescribes compounded depo-naltrexone in pellet form form for subcutaneous implantation in individually identified patients.
Section 503A also places limits on the type of drugs that may be used in compounding. According to Section 503A(b), a licensed pharmacist may compound a drug product using bulk drug substances that comply with the applicable USP or National Formulary (NF) monograph, when a monograph exists, as well as the USP chapter on pharmacy compounding. Naltrexone is covered by a USP monograph.
Any drug withdrawn from the market because it was found to be unsafe or not effective, or any drug which presents "demonstrable difficulties" for compounding that reasonably demonstrate an adverse effect on the safety or effectiveness of that drug product, may not be used in compounding.11 Naltrexone is an FDA approved drug that has not been withdrawn from the market for reasons concerning its safety or effectiveness, nor has it been identified by FDA as a drug which presents "demonstrable difficulties" for compounding. Therefore, it meets these criteria. Section 503A also places limits on the quantity of drug that may be compounded. This includes a prohibition on "regular" compounding, or compounding in "inordinate" amounts, of drug products which are essentially copies of commercially available drugs.12
Naltrexone is not commercially available in the pellet form prescribed by Dr. Gooberman. Orally administered forms of the drug are commercially available and are currently used as adjunctive therapy during the detoxification process for the purpose of blocking the pharmacological effects of exogenously administered opioids. The utility of orally administered naltrexone is limited, however, as dosing is dependent upon patient compliance. Because the drug is prescribed for patients whose lifestyles may make compliance extraordinarily difficult, the rate of relapse is high. Depo-naltrexone in the pellet form is considered significantly different from oral naltrexone. Thus, compounding of the drug in this form is not considered compounding of a drug that is otherwise commercially available, and this limitation therefore does not apply to the pellets compounded by Dr. Gooberman.
While compounding may be limited to a single formulation for a single patient, that is not necessarily the case. Under Section 503A, a pharmacist can compound larger quantities of a drug, such as depo-naltrexone, for multiple patients and still not need FDA approval. Accordingly, Dr. Gooberman's prescription of depo-naltrexone for multiple patients is not inconsistent with Section 503A.
The law also intends there to be limits on the quantity of compounded drugs that may be shipped across state lines by individual pharmacists or pharmacies. Specifically, Section 503A seeks to limit the interstate distribution of "inordinate amount" in this context is to be established by FDA with each state through a Memorandum of Understanding (MOU). FDA has said that it will not enforce this provision until an MOU is adopted. FDA has not yet adopted an MOU.
Thus, Dr. Gooberman's prescriptions for compounded depo-naltrexone comply with FDA's requirements. He therefore does not need to have clinical data to prescribe this compounded medication.
___________________________1. International Academy of Compounding Pharmacists, The Art and Skill of Compounding,http://iacprx.org/about_compounding.htm.2. N.J.A.C. § 13:39-1.2(1999).3. N.J.A.C. § 45:14-16(1999).4. N.J.A.C. § 13:39-9.8(1999).5. N.J.A.C. § 13:39-11.7(1999).6. N.J.A.C. § 13:39-11.10(1999).7. N.J.A.C. § 13:39-11.13(1999).8. United States Pharmacopeia, Pharmacy Compounding Practices, USP 24-NF 19,2118.9. 21 U.S.C. § 355(d)10. 21 U.S.C. § 353a.11. 21 U.S.C. § 503A(b)(1)(D).12. 21 U.S.C.§ 503A(b)(1)(D)
7/02/2012 04:06:00 PM
compounding naltrexone pellets,
Dr. Lance Gooberman,
Jeffrey N. Gibbs,
Pharmacy home delivery NJ
Thank you very much for informationPharmacy home delivery NJ
November 14, 2012 – Written testimony of Dr. Margaret A. Hamburg, M.D. before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations hearing “The Fungal Meningitis Outbreak: Could It Have Been Prevented?”November 14, 2012 – Video of the testimoney of Dr. Margaret A. Hamburg, M.D. before the House Committee on Energy and Commerce.November 15, 2012 – Written testimony of Dr. Margaret A. Hamburg, M.D., before the Senate Committee on Health, Education, Labor and Pensions “Pharmacy Compounding: Implications ofthe 2012 Meningitis Outbreak”.November 15, 2012 – Video of the Senate HELP Committee hearing.December 2012 - Transcript of FDA Meeting – “Framework for Pharmacy Compounding – State and Federal Roles”January 2013 – Comments Submitted to FDA Docket regarding “Framework for Pharmacy Compounding – State and Federal Roles”April 16, 2013 - Written testimony of Dr. Margaret A. Hamburg before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations – “Continuing Investigation into the Fungal Meningitis Outbreak: Could It Have Been Prevented?”April 16, 2013 – Video of testimony of Dr. Margaret A. Hamburg before the Energy and Commerce Committee.April 16, 2013 - House Energy and Commerce, Preliminary Majority Staff Report – “FDA’s Oversight of NDCC and AmeriDose: A History of Missed Opportunities?”April 26, 2013 – Senate HELP Committee posts Draft Compounding Legislation, asks for public input by 5/2/13.May 23, 2013 – “Examining Drug Compounding” – Testimony given by Dr. Janet Woodcock, Director CDER before the House Subcommittee on Health , Committee of Energy and Commerce.July 16, 2013 – “Reforming the Drug Compounding Regulatory Framework” – Statement given by Dr. Janet Woodcock, Director CDER before the House Subcommittee on Health, Committee of Energy and Commerce.July 31, 2013 – GAO Report – “Drug Compounding: Clear Authority and More Reliable Data Needed to Strengthen FDA Oversight“November 18, 2013 - Drug Quality and Security Act passes Senate on voice vote – passed House in September – goes to President Obama for signature.Bulk Drug Substances that May be Used to Compound Drug Products, etc., Concerning Outsourcing Facilities: Request for NominationsDraft Guidance for Industry and Staff: Interim Product Reporting for Human Drug Compounding Outsourcing Facilities under the Federal Food, Drug, and Cosmetic ActDraft Guidance for Industry and Staff: Pharmacy Compounding of Human Drug Products under the Federal Food, Drug, and Cosmetic Act; Availability; WithdrawalDraft Guidance for Industry and Staff: Registration for Human Drug Compounding Outsourcing Facilities under the Federal Food, Drug, and Cosmetic ActDrug Products that Present Demonstrable Difficulties for Compounding: Request for NominationsList of Bulk Drug Substances that May be Used in Pharmacy Compounding; Withdrawal Blog Archive
House Committee Report Finds Fault with FDA on Dru...
Exit the dragon Indian drug makers are trying to ...
CPPA Seeks Comments on Draft Standards for Communi...
Federal Investigation Takes Down New Breed of Pill...
Federal Pill Mill Investigation Results in Multipl...
K-V sues FDA over Makena in fight for survival
GlaxoSmithKline's (GSK) $3 Billion Whistleblower S...
FDA prompts companies to remove certain unapproved...
Simplified Test Method for Compounded Sterile Drug...
Bath Salts Compounds Are An Evolving Problem For D...
FDA Issues More Guidance About Makena®
FTC Workshop To Look at Pet Med Pricing
FY 2013 Food and Drug Administration Congressional...
Jeffrey N. Gibbs Statement on Behalf of Dr. Goober...
FDA Information for Veterinarians
Bodybuilding.com and Jeremy DeLuca: Criminal Charg...
Protocols To Minimize Risk of Errors When Compound...
Pharmacists Included as "Health Care Providers" Un...
Georgia law regarding office use
Import Alert 61-07
More retailers offering pet prescriptions--But Are...
Government Regulation of Compounding
American Society of Health-System Pharmacists (ASHP) discussion guide on USP Chapter 797 for compounding sterile preparations
Articles Addressing USP 797
CPG Sec. 608.400 Compounding of Drugs for Use in Animals
DEA, Diversion Control Pharmacists Manual
FDA Blog--FDA Voice
FDA Modernization Act of 1997 (FDAMA)
Fifth Circuit - Medical Center Pharmacy v. Mukasey, 06-51583, July 18, 2008
Guidance for FDA Staff and Industry, Compliance Policy Guides Manual, Sec 460.200, Pharmacy Compounding(6/7/2002)
International Journal Pharmaceutical Compounding (IJPC)
National Conference of State Legislation
Section 127, Application of Federal Law to Practice of Pharmacy Compounding
State Laws and Rules on Compounding
Supreme Court Decision - Thompson et al. v. Western States Medical Center et al., U.S. Supreme Court Case No. 01-344, Decided April 29, 2002
2013 Kentucky Pharmacy Law Review, Friday, April 19, 2013, Griffin Gate Marriott Resort & Spa, Lexington, KY
11th Annual Washingtom Health Law Summit
Drug Companies Start Buying Off Doctors In Med School Carl Lowe | Feb 28, 201
FDA understaffed
California State Board of Pharmacy 1625 N. Market Blvd, N219, Sacramento, CA 95834 Phone: (916) 574-7900 Fax: (916) 574-8618 www.pharmacy.ca.gov STATE AND CONSUMER SERVICES AGENCY DEPARTMENT OF CONSUMER AFFAIRS GOVERNOR EDMUND G. BROWN JR. Page 1 of 2 Meeting Materials will be available on the board’s Web site at www.pharmacy.ca.gov by March 18, 2013 NOTICE OF MEETING AND AGENDA Compounding Subcommittee March 19, 2013 Contact Person: Laura Hendricks (916) 574-7918 This committee meeting is open to the public and is accessible to the physically disabled. A person who needs a disability-related accommodation or modification in order to participate in the meeting may make a request by contacting Laura Hendricks at (916) 574-7918, by emailing laura.hendricks@dca.ca.gov or sending a written request to Ms. Hendricks at the Board of Pharmacy, 1625 N. Market Blvd., Suite N-219, Sacramento, CA 95834. Providing your request at least five business days before the meeting will help to ensure availability of the requested accommodation. DATE: March 19, 2013 PLACE: NOTE LOCATION: DCA Headquarters Building Two 1747 North Market Blvd Room 186 Sacramento, CA 95834 This meeting may be cancelled without notice. For verification of the meeting, call (916) 574-7900 or access the Board’s Web site at www.pharmacy.ca.gov. Discussion and action may be taken on any item on the agenda. The committee may discuss agenda items in any order. Time limitations for discussion and comment will be determined by the Committee Chair. Agenda Call to Order 10 a.m. I. General Background of Compounding Pharmacies in California II. Discussion Regarding California’s Amended Compounding Regulations to Take Effect April 1, 2013 – Amendments to 16 California Code of Regulations, Sections 1735.1, 1735.2 and 1751.2 III. Discussion Regarding the Introduction of the Board of Pharmacy’s Sponsored Legislation on Sterile Compounding, Senate Bill 294 (Emmerson) IV. Discussion Regarding USP’s 797 Standards and Regulation Requirements of the Board of Pharmacy V. Discussion Regarding “Batches” VI. Discussion of the Board of Pharmacy’s Questions and Answers Document on Compounding VII. General Discussion VIII. Closing Comments X. Public Comment on Items Not on the Agenda/Agenda Items For Future Meetings Note: The committee may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether to place the matter on the agenda of a future meeting. [Government Code Sections 11125, 11125.7(a)] ADJOURNMENT 4 p.m. California State Board of Pharmacy – Compounding Subcommittee Meeting – March 19, 2013 Criminalization of Medication Errors; Mistakes by Pharmacists
lawofcompoundindmedications.com. Ethereal template. Powered by Blogger.